Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

HOLD

Attractive stock for a long-term investor. Has been consistently beating estimates and estimates have been rising. As volatility comes out of the market, people are going to be willing to pay for this level of quality.

TOP PICK

Have medical devices, consumer products and pharmaceuticals. Acquisition of Pfizer's consumer products division in 2006 was very good. Fantastic balance sheet. Net cash.

TOP PICK

Good company to own in this kind of a difficult market. Not only a pharmaceutical and medical devices company but also a consumers product company. Made an astute acquisition of Pfizer's (PFE-N) consumers’ products. Almost 6% dividend.

TRADE

Have medical Device business, Consumer business, great company, a lot of which is not sensitive to politics.

BUY

Very interesting, very stable.

BUY

Diversified medical supply and pharmaceutical. Hitting new highs but valuation is still among the cheapest at 15X earnings. Double-digit growth through many years. 2.6% yield. Has a little bit of upside left. Long-term hold.

BUY

Consumer products and pharmaceuticals. Has the confidence of the shareholders and has done very well. Strong balance sheet. Stable company. Well-placed for a growth environment.

BUY

Great company and has been an excellent stock. Really isn't a pharmaceutical stock. Big in medical devices. Also a large consumers product company.

TOP PICK

Recently had a huge breakout. Had not cleared the $70 for ages. People who had shorted are now scrambling to cover. You don't want to be in this event starts coming back too far.

BUY

Home healthcare products and health/beauty aids are very solid products in the US. Less enthusiastic about the medical devices business and pharmaceuticals but overall it is a tremendously strong company with a very good dividend. Has been undervalued for about 5 years.

TOP PICK

(Sneaked in a 4th Top Pick.) An absolutely unbelievable technical breakout. Had not gone past its $69-$70 level since 2005. See it heading towards the $100 level.

BUY

Medical Device manufacturing. Should be a core holding for conservative investors. They have good growth projects. 40%-50% international exposure

BUY

Stable cash flow. A solid name to own in these volatile markets.

DON'T BUY

Over time, the model price has been coming down. He has a model price of $60.18, a -14% differential.

TOP PICK

Medical devices and pharmaceuticals have been doing very well. Has a global franchise and growing very nicely outside of North America. Positive earnings revisions.

Showing 496 to 510 of 626 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)